Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
JANX Stock Chart & Stats
$13.11
-$2.71(-4.69%)
At close: 4:00 PM EST
$13.11
-$2.71(-4.69%)
Day’s Range― - ―
52-Week Range$12.12 - $38.42
Previous CloseN/A
Volume1.13M
Average Volume (3M)1.52M
Market Cap
$788.54M
Enterprise Value$764.61M
Total Cash (Recent Filing)$988.99M
Total Debt (Recent Filing)$22.66M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Mar 06, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding60,147,808
10 Day Avg. Volume1,334,493
30 Day Avg. Volume1,516,088
Financial Highlights & Ratios
PEG Ratio13.76
Price to Book (P/B)2.81
Price to Sales (P/S)271.80
P/FCF Ratio-65.15
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue76.46
Enterprise Value/Gross Profit80.49
Enterprise Value/Ebitda-5.82
Forecast
1Y Price Target
$52.58Price Target Upside301.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-2.83
Revenue Forecast (FY)$1.97M
Bulls Say, Bears Say
Bulls Say
Clinical Expansion And Market OpportunityInitiation of a Phase 1b expansion into earlier-line prostate cancer opens access to a substantially larger patient population and increases the potential commercial opportunity for JANX007.
Safety Profile And TolerabilityAn updated CRS mitigation protocol produced predominantly low-grade events and no severe CRS cases, supporting the program's tolerability and partner interest.
Strategic CollaborationBristol Myers Squibb's exclusive collaboration and license validates Janux's tumor-activated platform and brings external development and commercialization resources while Janux leads early clinical work.
Bears Say
Competitive Differentiation And Efficacy ParityObjective response and progression outcomes that align with an existing approved therapy reduce JANX007's differentiation and could limit its market share in a crowded treatment setting.
Dose Selection And Pivotal Trial RiskUncertainty around the final recommended Phase 2 dose and dosing schedule for JANX007 creates execution risk for pivotal trial design and regulatory timing.
Serious Safety SignalA fatal cardiotoxicity event linked to the program raises regulatory scrutiny and may require enhanced cardiac monitoring and safety safeguards in future studies.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $12.12 and its highest was $38.42 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Janux Therapeutics Inc’s market cap is $788.54M.
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is Mar 06, 2026 which is in 20 days.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.612 by $0.222.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -0.62.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 60,147,808 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.612. Following the earnings report the stock price went down -7.606%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.58 (301.07% Upside)
$52.58 (301.07% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 275.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $173.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.69%
12-Months-Change
Fundamentals
Return on Equity
-12.48%
Trailing 12-Months
Asset Growth
47.44%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$52.58
▲(301.07% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
Currently, No data available
---